180 related articles for article (PubMed ID: 31754326)
41. GATA3 in Breast Cancer: Tumor Suppressor or Oncogene?
Takaku M; Grimm SA; Wade PA
Gene Expr; 2015; 16(4):163-8. PubMed ID: 26637396
[TBL] [Abstract][Full Text] [Related]
42. P2Y2 nucleotide receptor-mediated extracellular signal-regulated kinases and protein kinase C activation induces the invasion of highly metastatic breast cancer cells.
Eun SY; Ko YS; Park SW; Chang KC; Kim HJ
Oncol Rep; 2015 Jul; 34(1):195-202. PubMed ID: 26063340
[TBL] [Abstract][Full Text] [Related]
43. Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer.
Hung SW; Chiu CF; Chen TA; Chu CL; Huang CC; Shyur LF; Liang CM; Liang SM
Breast Cancer Res Treat; 2012 Nov; 136(1):89-105. PubMed ID: 22983836
[TBL] [Abstract][Full Text] [Related]
44. The Significance and Therapeutic Potential of GATA3 Expression and Mutation in Breast Cancer: A Systematic Review.
Du F; Yuan P; Wang T; Zhao J; Zhao Z; Luo Y; Xu B
Med Res Rev; 2015 Nov; 35(6):1300-15. PubMed ID: 26313026
[TBL] [Abstract][Full Text] [Related]
45. Sohlh2 suppresses epithelial to mesenchymal transition in breast cancer via downregulation of IL-8.
Ji S; Zhang W; Zhang X; Hao C; Hao A; Gao Q; Zhang H; Sun J; Hao J
Oncotarget; 2016 Aug; 7(31):49411-49424. PubMed ID: 27384482
[TBL] [Abstract][Full Text] [Related]
46. ELK3-GATA3 axis modulates MDA-MB-231 metastasis by regulating cell-cell adhesion-related genes.
Kim KS; Kim J; Oh N; Kim MY; Park KS
Biochem Biophys Res Commun; 2018 Apr; 498(3):509-515. PubMed ID: 29510139
[TBL] [Abstract][Full Text] [Related]
47. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
48. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
[TBL] [Abstract][Full Text] [Related]
49. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
Tordjman J; Majumder M; Amiri M; Hasan A; Hess D; Lala PK
BMC Cancer; 2019 Jun; 19(1):561. PubMed ID: 31185986
[TBL] [Abstract][Full Text] [Related]
50. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
[TBL] [Abstract][Full Text] [Related]
51. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
[TBL] [Abstract][Full Text] [Related]
52. Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.
Mathenge EG; Dean CA; Clements D; Vaghar-Kashani A; Photopoulos S; Coyle KM; Giacomantonio M; Malueth B; Nunokawa A; Jordan J; Lewis JD; Gujar SA; Marcato P; Lee PW; Giacomantonio CA
Neoplasia; 2014 Nov; 16(11):950-60. PubMed ID: 25425969
[TBL] [Abstract][Full Text] [Related]
53. RNF8 promotes epithelial-mesenchymal transition of breast cancer cells.
Kuang J; Li L; Guo L; Su Y; Wang Y; Xu Y; Wang X; Meng S; Lei L; Xu L; Shao G
J Exp Clin Cancer Res; 2016 Jun; 35(1):88. PubMed ID: 27259701
[TBL] [Abstract][Full Text] [Related]
54. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
55. NTN4 is associated with breast cancer metastasis via regulation of EMT-related biomarkers.
Xu X; Yan Q; Wang Y; Dong X
Oncol Rep; 2017 Jan; 37(1):449-457. PubMed ID: 27840993
[TBL] [Abstract][Full Text] [Related]
56. miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial-mesenchymal transition.
Yu Y; Luo W; Yang ZJ; Chi JR; Li YR; Ding Y; Ge J; Wang X; Cao XC
Mol Cancer; 2018 Mar; 17(1):70. PubMed ID: 29510731
[TBL] [Abstract][Full Text] [Related]
57. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.
Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG
Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057
[TBL] [Abstract][Full Text] [Related]
58. Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.
Lu S; Yakirevich E; Wang LJ; Resnick MB; Wang Y
BMC Cancer; 2019 Nov; 19(1):1085. PubMed ID: 31718619
[TBL] [Abstract][Full Text] [Related]
59. miR-219a-5p inhibits breast cancer cell migration and epithelial-mesenchymal transition by targeting myocardin-related transcription factor A.
Zhuang C; Yuan Y; Song T; Wang H; Huang L; Luo X; He H; Huo L; Zhou H; Wang N; Zhang T
Acta Biochim Biophys Sin (Shanghai); 2017 Dec; 49(12):1112-1121. PubMed ID: 29077787
[TBL] [Abstract][Full Text] [Related]
60. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
Xue Y; Xu W; Zhao W; Wang W; Zhang D; Wu P
Biomed Pharmacother; 2017 Feb; 86():426-433. PubMed ID: 28012397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
